Given the current state of molecular classification in endometrial cancer [8,9,11] and the growing adoption of universal screening for Lynch syndrome [9,28,29], it is assumed that the MMR IHC will be performed on the vast majority of endometrial cancers. The gene discussed is MRC1; the disease is endometrial cancer.